SCHEMBL3475787

SCHEMBL3475787

COC(=O)c1cccc(C(C)N)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.54
SLC7A5 Q01650 1/20 0.54
ALDH1A1 P00352 2/20 0.50
TSHR P16473 1/20 0.50
PTGS1 P23219 1/20 0.49
PTGS2 P35354 1/20 0.49
CYP4F2 P78329 2/20 0.49
CYP4A11 Q02928 2/20 0.49
RAB9A P51151 3/20 0.47
POLB P06746 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
CASR P41180 1/20 0.46
NPC1 O15118 2/20 0.46
MAPT P10636 2/20 0.46
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29779050 1.00 LOXL2 (0.54) LOXL2SLC7A5ALDH1A1TSHRPTGS1
SCHEMBL14561093 1.00 LOXL2 (0.54) LOXL2SLC7A5ALDH1A1TSHRPTGS1
SCHEMBL14551931 1.00 LOXL2 (0.54) LOXL2SLC7A5ALDH1A1TSHRPTGS1
SCHEMBL4410700 0.88 LOXL2 (0.56) LOXL2SLC7A5ALDH1A1TSHRPTGS1
SCHEMBL4410705 0.88 LOXL2 (0.56) LOXL2SLC7A5ALDH1A1TSHRPTGS1
SCHEMBL13099306 0.88 LOXL2 (0.56) LOXL2SLC7A5ALDH1A1TSHRPTGS1
SCHEMBL15630895 0.87 LOXL2 (0.51) LOXL2SLC7A5ALDH1A1TSHRPTGS1
SCHEMBL84441 0.86 TSHR (0.53) LOXL2SLC7A5ALDH1A1TSHRPTGS1
SCHEMBL246026 0.84 TSHR (0.52) LOXL2SLC7A5ALDH1A1TSHRPTGS1
SCHEMBL698948 0.84 TSHR (0.52) LOXL2SLC7A5ALDH1A1TSHRPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109415553-B Plasticized thermoset resins and related cured resins, curing methods, and articles comprising cured resins 马萨诸塞大学 2022-08-05 CN claimed
EP-3481899-A1 PLASTICIZED THERMOSET RESIN, AND ASSOCIATED CURED RESIN, METHOD OF CURING, AND ARTICLE COMPRISING CURED RESIN The University of Massachusetts (US) 2019-05-15 EP claimed
CN-109415553-A The thermosetting resin of plasticising and related solidified resin, curing method and the product comprising solidified resin 马萨诸塞大学 2019-03-01 CN claimed
WO-2018008003-A1 PLASTICIZED THERMOSET RESIN, AND ASSOCIATED CURED RESIN, METHOD OF CURING, AND ARTICLE COMPRISING CURED RESIN THE UNIVERSITY OF MASSACHUSETTS (US) 2018-01-11 WO claimed
US-12240828-B2 Heteroaromatic compounds as vanin inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-03-04 US disclosed
EP-3890828-B1 HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2025-02-19 EP disclosed
EP-3481899-B1 PLASTICIZED THERMOSET RESIN, AND ASSOCIATED CURED RESIN, METHOD OF CURING, AND ARTICLE COMPRISING CURED RESIN UNIV MASSACHUSETTS (US) 2022-12-21 EP disclosed
CN-109415553-B Plasticized thermoset resins and related cured resins, curing methods, and articles comprising cured resins 马萨诸塞大学 2022-08-05 CN disclosed
CN-108929263-B Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2022-07-22 CN disclosed
US-20220048889-A1 HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-02-17 US disclosed
US-20220048889-A1 HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-02-17 US disclosed
EP-3890828-A1 HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS Boehringer Ingelheim International GmbH (DE) 2021-10-13 EP disclosed
EP-2099774-A1 INHIBITORS OF KINASE ACTIVITY Cytopia Research Pty Ltd (AU) 2009-09-16 EP disclosed
WO-2009012375-A2 SQUARATE KINASE INHIBITORS WYETH (US) 2009-01-22 WO disclosed
WO-2008058341-A1 INHIBITORS OF KINASE ACTIVITY CYTOPIA RESEARCH PTY LTD (AU) 2008-05-22 WO disclosed
US-20080070894-A1 Novel Substituted Imidazole Derivative MSD K.K. (JP) 2008-03-20 US disclosed
CN-101048406-A Novel substituted imidazole derivatives BANYU PHARMA CO LTD (JP) 2007-10-03 CN disclosed
EP-1790650-A1 NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-05-30 EP disclosed
US-5424441-A Nootropic, antiepileptic agents CIBA-GEIGY CORPORATION (US) 1995-06-13 US disclosed
US-5332729-A Nootropic, antiepileptic agents CIBA-GEIGY CORPORATION (US) 1994-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070894-A1 Novel Substituted Imidazole Derivative PLK1, CDK1, CDK11A LOXL2 3965/4885SLC7A5 1897/4885ALDH1A1 4349/4885
US-12240828-B2 Heteroaromatic compounds as vanin inhibitors VHL, FANCI, PAH LOXL2 1797/4885SLC7A5 793/4885ALDH1A1 543/4885
US-20220048889-A1 HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS VHL, FANCI, PAH LOXL2 1797/4885SLC7A5 793/4885ALDH1A1 543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.